AbbVie Is Focused on Growth Opportunities in Neuroscience Space

Diversification Is Key to AbbVie’s Long-Term Growth Prospects PART 7 OF 12 By Margaret Patrick | Nov 29, 2016 2:00 pm EST Neuroscience opportunities To diversify its product portfolio, AbbVie (ABBV) has been focusing on patients suffering with neurodegenerative disorders such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. There’s significant unmet demands in these areas due to limited treatment options. If AbbVie expands in the underserved neuroscience space, it may have a positive impact on the company’s share prices as well as those of the Vanguard Growth ETF (VUG). AbbVie makes up about 1.1% of VUG’s total portfolio holdings. Parkinson’s disease On January 12, 2015, the FDA (U.S. Food and Drug Administration) approved Duopa as a therapy for motor fluctuations for patients suffering with advanced Parkinson’s disease. According to…